Thus, controlling MECP2 levels, activity, or downstream targets by targeting MECP2 PTMs could be a feasible approach for developing specific therapies against the detrimental effects of MECP2 during AD pathogenesis. This evidence concerns the gene MECP2 and Alzheimer disease.